{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McMullan B"],"funding":["World Health Organization"],"pagination":["myae038"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210620"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["62(6)"],"pubmed_abstract":["This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%-30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppress"],"journal":["Medical mycology"],"pubmed_title":["Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list."],"pmcid":["PMC11210620"],"funding_grant_id":["001"],"pubmed_authors":["McMullan B","Morrissey CO","Nahrgang SA","Sati H","Tacconelli E","Alastruey-Izquierdo A","Tanti D","Oladele R","Galas M","Shin JH","Govender NP","Ford NP","Heim J","Beardsley J","Kim HY","Dao A","Huttner B","Gigante V","Alffenaar JW"],"additional_accession":[]},"is_claimable":false,"name":"Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list.","description":"This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority Pathogens List. PubMed and Web of Science were used to find studies reporting mortality, inpatient care, complications/sequelae, antifungal susceptibility/resistance, preventability, annual incidence, global distribution, and emergence in the past 10 years, published from January 2011 to February 2021. Reported mortality is highly variable, depending on the patient population: In studies of persons with HIV, mortality was reported at 5%-30%, while in studies of persons without HIV, mortality ranged from 4% to 76%. Risk factors for disease principally include immunosuppress","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-05-05T18:15:50.037Z","creation":"2025-04-19T18:33:25.899Z"},"accession":"S-EPMC11210620","cross_references":{"pubmed":["38935910"],"doi":["10.1093/mmy/myae038"]}}